Edwards Lifesciences recently announced significant findings at the ACC Annual Scientific Session, showcasing crucial research in the treatment of structural heart disease. This development, alongside data indicating the increased effectiveness of electronic notifications in treating severe aortic stenosis, comes amid broader market volatility. The past week saw a 1.58% rise in Edwards Lifesciences' stock, contrasting with a 3.4% drop in the overall market as concerns about tariffs loomed. Investors might have responded positively to the company's advances in healthcare technology amid a generally declining market focused on economic uncertainties.

Buy, Hold or Sell Edwards Lifesciences? View our complete analysis and fair value estimate and you decide.

AI is about to change healthcare. These 24 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Over the last five years, Edwards Lifesciences achieved a total shareholder return of 11.27%, reflecting moderate long-term growth amidst strategic developments and challenges. This performance was partly driven by advancements in their Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT) technologies. The anticipated FDA approvals and strong adoption of their PASCAL and EVOQUE systems were key contributors. However, the company faced challenges such as lower-than-expected TAVR growth and rising Selling, General, and Administrative expenses, which added financial pressure.

During the past year, Edwards Lifesciences underperformed the US Medical Equipment industry, which saw a return of 2.4%. Over the period, the expansion of their buyback program, totaling US$4 billion, also played a role in buoying investor sentiment. Legal challenges, including a class action lawsuit, briefly impacted stock performance but did not deter the company's innovation drive, as evidenced by its ongoing efforts to expand and enhance its cardiac care offerings globally.

Click here and access our complete financial health analysis report to understand the dynamics of Edwards Lifesciences.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NYSE:EW.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com